{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:55:52Z","timestamp":1787021752903,"version":"build-2736575974"},"reference-count":88,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031A307"],"award-info":[{"award-number":["031A307"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1006155","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T13:25:28Z","timestamp":1528982728000},"page":"e1006155","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-6706","authenticated-orcid":true,"given":"Sulav","family":"Duwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-0967","authenticated-orcid":true,"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-6394","authenticated-orcid":true,"given":"Max","family":"von Kleist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"issue":"5988","key":"ref1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1126\/science.1191047","article-title":"HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals","volume":"329","author":"D Trono","year":"2010","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"YC Ho","year":"2013","journal-title":"Cell"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrmicro3352","article-title":"Eradicating HIV-1 infection: seeking to clear a persistent pathogen","volume":"12","author":"NM Archin","year":"2014","journal-title":"Nature Reviews Microbiology"},{"key":"ref4","unstructured":"UNAIDS. AIDS by the numbers. (<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/AIDS-by-the-numbers-2016_en.pdf\" xlink:type=\"simple\">http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/AIDS-by-the-numbers-2016_en.pdf<\/ext-link>), accessed 18-Dec-2017; 2016."},{"issue":"27","key":"ref5","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"10013","key":"ref6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"S McCormack","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"ref7","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1097\/QAD.0b013e32834d3cab","article-title":"The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis","volume":"25","author":"SB Keller","year":"2011","journal-title":"AIDS"},{"key":"ref8","unstructured":"AIDS Vaccine Advocacy Coalition. Pre-Exposure Prophylaxis (PrEP) by the Numbers, (available at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.avac.org\/sites\/default\/files\/resource-files\/prep_BTN_aug2016.pdf\" xlink:type=\"simple\">http:\/\/www.avac.org\/sites\/default\/files\/resource-files\/prep_BTN_aug2016.pdf<\/ext-link>, accessed 22-Oct- 2017.)."},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1137\/120876800","article-title":"Stochastic analysis of pre- and postexposure prophylaxis against HIV infection","volume":"73","author":"JM Conway","year":"2013","journal-title":"SIAM J Appl Math"},{"issue":"1-2","key":"ref10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mbs.2008.03.005","article-title":"The probability of HIV infection in a new host and its reduction with microbicides","volume":"214","author":"HC Tuckwell","year":"2008","journal-title":"Math Biosci"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/psp4.12095","article-title":"Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1","volume":"5","author":"S Duwal","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"e1004923","DOI":"10.1371\/journal.pcbi.1004923","article-title":"Stochastic simulation of biomolecular networks in dynamic environments","volume":"12","author":"M Voliotis","year":"2016","journal-title":"PLoS Comput Biol"},{"issue":"21","key":"ref13","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"BF Keele","year":"2008","journal-title":"PNAS"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/JVI.02132-08","article-title":"Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants","volume":"83","author":"MR Abrahams","year":"2009","journal-title":"J Virol"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"e12303","DOI":"10.1371\/journal.pone.0012303","article-title":"Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing","volume":"5","author":"W Fischer","year":"2010","journal-title":"PloS one"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"e1000890","DOI":"10.1371\/journal.ppat.1000890","article-title":"High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men","volume":"6","author":"H Li","year":"2010","journal-title":"PLoS Pathog"},{"issue":"15","key":"ref17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJM199704103361507","article-title":"Sexual transmission of HIV","volume":"336","author":"RA Royce","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1473-3099(09)70021-0","article-title":"Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies","volume":"9","author":"MC Boily","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"093001","DOI":"10.1088\/1751-8121\/aa54d9","article-title":"Approximation and inference methods for stochastic biochemical kinetics\u2014a tutorial review","volume":"50","author":"D Schnoerr","year":"2017","journal-title":"Journal of Physics A Mathematical and Theoretical"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"026601","DOI":"10.1088\/0034-4885\/77\/2\/026601","article-title":"Noise in biology","volume":"77","author":"LS Tsimring","year":"2014","journal-title":"Reports on progress in physics Physical Society"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.physchem.58.032806.104637","article-title":"Stochastic Simulation of Chemical Kinetics","volume":"58","author":"DT Gillespie","year":"2007","journal-title":"Annu Rev Phys Chem"},{"key":"ref22","unstructured":"Kurtz TG. Approximation of population processes. vol. 36. CBMS-NSF Regional Conference Series in Applied Mathematics ed. SIAM; 1981."},{"key":"ref23","unstructured":"Duwal S, Dickinson L, Khoo SH, von Kleist M. Mechanistic framework predicts utility of antiretroviral drugs for HIV prophylaxis. submitted for publication 2017."},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"e1000720","DOI":"10.1371\/journal.pcbi.1000720","article-title":"Drug-class specific impact of antivirals on the reproductive capacity of HIV","volume":"6","author":"M von Kleist","year":"2010","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"e18204","DOI":"10.1371\/journal.pone.0018204","article-title":"HIV Quasispecies Dynamics during Pro-active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs","volume":"6","author":"M von Kleist","year":"2011","journal-title":"PLoS One"},{"issue":"16","key":"ref26","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1128\/JVI.00296-09","article-title":"Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization","volume":"83","author":"J Isaacman-Beck","year":"2009","journal-title":"J Virol"},{"issue":"13","key":"ref27","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1128\/JVI.03577-12","article-title":"Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design","volume":"87","author":"LH Ping","year":"2013","journal-title":"J Virol"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0025-5564(97)00094-1","article-title":"Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies","volume":"147","author":"WY Tan","year":"1998","journal-title":"Math Biosci"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/jtbi.2000.1076","article-title":"Modeling plasma virus concentration during primary HIV infection","volume":"203","author":"MA Stafford","year":"2000","journal-title":"J Theor Biol"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nri700","article-title":"Modelling viral and immune system dynamics","volume":"2","author":"AS Perelson","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejps.2016.01.016","article-title":"Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1","volume":"94","author":"S Duwal","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0025-5564(93)90043-A","article-title":"Dynamics of HIV infection of CD4+ T cells","volume":"114","author":"AS Perelson","year":"1993","journal-title":"Math Biosci"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"e1001058","DOI":"10.1371\/journal.pcbi.1001058","article-title":"Stochastic theory of early viral infection: continuous versus burst production of virions","volume":"7","author":"JE Pearson","year":"2011","journal-title":"PLoS Comput Biol"},{"issue":"17","key":"ref34","doi-asserted-by":"crossref","first-page":"8518","DOI":"10.1128\/JVI.76.17.8518-8513.2002","article-title":"Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection","volume":"76","author":"TC Pierson","year":"2002","journal-title":"J Virol"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/JVI.79.4.2199-2210.2005","article-title":"Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells","volume":"79","author":"Y Zhou","year":"2005","journal-title":"J Virol"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacolog Rev"},{"issue":"7","key":"ref37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"L Shen","year":"2008","journal-title":"Nat Med"},{"issue":"19","key":"ref38","doi-asserted-by":"crossref","first-page":"e90033","DOI":"10.1172\/jci.insight.90033","article-title":"Quantitative evaluation of the antiretroviral efficacy of dolutegravir","volume":"1","author":"SB Laskey","year":"2016","journal-title":"JCI Insight"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"DA Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"ref40","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.bmcl.2013.02.070","article-title":"HCV versus HIV drug discovery: D\u00e9j\u00e0 vu all over again?","volume":"23","author":"WJ Watkins","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/088922203769232629","article-title":"Protein binding in antiretroviral therapies","volume":"19","author":"M Boffito","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10928-007-9071-3","article-title":"Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution","volume":"34","author":"M von Kleist","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref43","article-title":"Mixed-effects model in S and S-Plus","author":"JC Pinheiro","year":"2009"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkv425","article-title":"Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake","volume":"71","author":"E Elliot","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"ref45","unstructured":"Bracchi M, Pagani N, Clarke A, Adams T, Waters L, Bolton M, et al. Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity. In: International Congress of Drug Therapy in HIV Infection, Glasgow, UK, Abstract P209; 2016."},{"key":"ref46","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-9485-1","article-title":"Pharmacokinetic-pharmacodynamic modeling and simulation","author":"PL Bonate","year":"2011"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/j100540a008","article-title":"Exact stochastic simulation of coupled chemical reactions","volume":"81","author":"DT Gillespie","year":"1977","journal-title":"J Phys Chem"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","article-title":"Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection","volume":"95","author":"TW Chun","year":"1998","journal-title":"PNAS"},{"issue":"6","key":"ref49","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/ni.3152","article-title":"HIV reservoirs as obstacles and opportunities for an HIV cure","volume":"16","author":"TW Chun","year":"2015","journal-title":"Nat Immunol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature13594","article-title":"Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys","volume":"512","author":"JB Whitney","year":"2014","journal-title":"Nature"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/QAI.0000000000001122","article-title":"Inferring HIV-1 Transmission Dynamics in Germany From Recently Transmitted Viruses","volume":"73","author":"KP Yousef","year":"2016","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"9635","key":"ref52","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(08)61115-0","article-title":"Relation between HIV viral load and infectiousness: a model-based analysis","volume":"372","author":"DP Wilson","year":"2008","journal-title":"Lancet"},{"issue":"13","key":"ref53","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","article-title":"Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group","volume":"342","author":"TC Quinn","year":"2000","journal-title":"N Engl J Med"},{"issue":"23","key":"ref54","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"JM Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"e40382","DOI":"10.1371\/journal.pone.0040382","article-title":"Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection","volume":"7","author":"S Duwal","year":"2012","journal-title":"PLoS One"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","article-title":"Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm","volume":"29","author":"JE Haberer","year":"2015","journal-title":"AIDS"},{"key":"ref57","unstructured":"Grant R, Anderson P, McMahan V, Liu A, Amico K, Mehrotra M, et al. Results of the iPrEx open-label extension (iPrEx OLE) in men and transgender women who have sex with men: PrEP uptake, sexual practices, and HIV incidence. AIDS. 2014; p. 20\u201325."},{"key":"ref58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"JM Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"The New England journal of medicine"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/S2352-3018(16)30113-8","article-title":"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment","volume":"3","author":"I McGowan","year":"2016","journal-title":"Lancet HIV"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"M Markowitz","year":"2017","journal-title":"Lancet HIV"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"McMillan J, Szlachetka A, Slack L, Sillman B, Lamberty B, Morsey B, et al. Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrobial agents and chemotherapy. 2017; p. AAC\u201301316.","DOI":"10.1128\/AAC.01316-17"},{"issue":"1","key":"ref63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/bib\/bbn050","article-title":"Biochemical simulations: stochastic, approximate stochastic and hybrid approaches","volume":"10","author":"J Pahle","year":"2009","journal-title":"Brief Bioinform"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.csbj.2014.10.003","article-title":"Stochastic simulation in systems biology","volume":"12","author":"T Sz\u00fakely","year":"2014","journal-title":"Comput Struct Biotechnol J"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1137\/110825716","article-title":"Hybrid stochastic-deterministic solution of the chemical master equation","volume":"10","author":"S Menz","year":"2012","journal-title":"Multiscale Modeling & Simulation"},{"issue":"4","key":"ref66","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1137\/110821500","article-title":"On reduced models for the chemical master equation","volume":"9","author":"T Jahnke","year":"2011","journal-title":"Multiscale Modeling & Simulation"},{"key":"ref67","article-title":"Method of conditional moments (MCM) for the Chemical Master Equation: A unified framework for the method of moments and hybrid stochastic-deterministic models","author":"J Hasenauer","year":"2013","journal-title":"J Math Biol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14740338.2015.973845","article-title":"Evaluation of dolutegravir safety for the treatment of HIV-1","volume":"14","author":"SW Keeshin","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"JJ Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3851\/IMP1919","article-title":"Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract","volume":"16","author":"LJ Else","year":"2011","journal-title":"Antivir Ther"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/clpt.2011.99","article-title":"The male genital tract is not a pharmacological sanctuary from efavirenz","volume":"90","author":"LB Avery","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"ref72","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"MS Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/JVI.69.8.5087-5094.1995","article-title":"Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase","volume":"69","author":"LM Mansky","year":"1995","journal-title":"J Virol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"DIS Rosenbloom","year":"2012","journal-title":"Nat Med"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","author":"AS Perelson","year":"1997","journal-title":"Nature"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrmicro772","article-title":"HIV-1 dynamics in vivo: implications for therapy","volume":"1","author":"V Simon","year":"2003","journal-title":"Nat Rev Microbiol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nm0703-853","article-title":"HIV-1 pathogenesis","volume":"9","author":"M Stevenson","year":"2003","journal-title":"Nat Med"},{"issue":"5","key":"ref78","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy","volume":"5","author":"D Finzi","year":"1999","journal-title":"Nat Med"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJM199905273402101","article-title":"Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy","volume":"340","author":"L Zhang","year":"1999","journal-title":"N Engl J Med"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/518250","article-title":"Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus","volume":"195","author":"TW Chun","year":"2007","journal-title":"J Infect Dis"},{"key":"ref81","first-page":"238","article-title":"Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069\/ACTG A5305)","volume":"215","author":"RM Gulick","year":"2017","journal-title":"Journal Infect Dis"},{"issue":"6510","key":"ref82","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"X Wei","year":"1995","journal-title":"Nature"},{"issue":"2","key":"ref83","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/135965350901400212","article-title":"Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir","volume":"14","author":"AR Sedaghat","year":"2009","journal-title":"Antivir Ther"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1128\/JVI.77.8.5037-5038.2003","article-title":"A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo","volume":"77","author":"M Markowitz","year":"2003","journal-title":"J Virol"},{"issue":"3","key":"ref85","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/525283","article-title":"Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro","volume":"197","author":"KK Koelsch","year":"2008","journal-title":"J Infect Dis"},{"issue":"12","key":"ref86","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1073\/pnas.0711372105","article-title":"Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle","volume":"105","author":"AR Sedaghat","year":"2008","journal-title":"PNAS"},{"issue":"12","key":"ref87","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1128\/AAC.00741-11","article-title":"Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes","volume":"55","author":"M Frank","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref88","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bcp.12639","article-title":"Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients","volume":"80","author":"J Zhang","year":"2015","journal-title":"Br J Clin Pharmacol"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1006155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T14:44:03Z","timestamp":1661438643000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1006155"}},"subtitle":[],"editor":[{"given":"Katia","family":"Koelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":88,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1006155","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]}}}